Biotech Fluidics announce the foundation of Ventri Labs AB (VentriLabs) – a new subsidiary set-up to leverage the disruptive benefits of its patented gravity liquid pump technology for handling of sensitive media.
Use of conventional mechanical pumps is known to negatively affect sensitive biological materials limiting their use in bioprocessing, clinical and tissue engineering applications. Meticulously engineered to ensure delicate handling of sensitive media VentriLabs´ gravity-based pump technology is proven to reduce destructive mechanical and shearing effects by up to 95% while pumping blood, as compared to commonly used peristaltic pumps.
This innovative technology is also highly controllable, eliminating pulsation effects inherent in peristaltic and membrane pumps. In filtration applications this equates to improved efficiency and yields that translate into a more cost-efficient process for the user.
VentriLabs´ innovative gravity pump technology offers gentle pumping in bioprocess applications.
Dr Robin Öz, CEO of VentriLabs commented “Having committed multi-year funding from our parent company and a strong intellectual property portfolio – we are inviting collaborative partners and investors to accelerate the process, and further development of our groundbreaking liquid pump technology in lab, process and clinical applications.”
For further information about gravity liquid pump technology please visit www.ventrilabs.com or contact the VentriLabs on +46 (0) 300 52 13 86 / [email protected]
